Trident Lifeline Limited has received an award from the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) for its outstanding contribution to India's Pharmaceutical Exports during the year 2024-25. The award was presented to the Company on Monday, 7th September 2026, at New Delhi, during the 12th edition of the International Pharmaceutical Exhibition held at Hall No. 2 FF, Bharat Mandapam, Pragati Maidan, New Delhi – 110001.
The event witnessed participation of more than 750 foreign delegates representing over 100 countries, serving as an important international platform for pharmaceutical industry leaders, government representatives, and global stakeholders.
This recognition is described as a testament to the Company's continued contribution to the growth and development of India's pharmaceutical export sector and its endeavor to strengthen India's presence in the global pharmaceutical market. The Company states it remains committed to contributing meaningfully to the growth of India's pharmaceutical industry and enhancing its global presence.
The disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for investor information and records.
Company Background
Trident Lifeline Limited is a pharmaceutical and healthcare company with expertise in manufacturing finished dose pharmaceutical products. The Company offers a diversified portfolio spanning pharmaceuticals, nutraceuticals, herbal products, injectables, personal care and medical devices. Its operations are supported by a hybrid manufacturing model combining strategic manufacturing partnerships with integrated capabilities.
Safe Harbour Statement
The document includes a standard safe harbor statement noting that certain forward-looking statements are subject to risks and uncertainties including government actions, local, political or economic developments, technological risks, and other factors that could cause actual results to differ materially from those contemplated.